HomeCompareZEOOY vs JNJ

ZEOOY vs JNJ: Dividend Comparison 2026

ZEOOY yields 1.99% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ZEOOY wins by $62.99M in total portfolio value
10 years
ZEOOY
ZEOOY
● Live price
1.99%
Share price
$9.73
Annual div
$0.19
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.02M
Annual income
$57,473,081.47
Full ZEOOY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — ZEOOY vs JNJ

📍 ZEOOY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZEOOYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZEOOY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZEOOY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZEOOY
Annual income on $10K today (after 15% tax)
$169.30/yr
After 10yr DRIP, annual income (after tax)
$48,852,119.25/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, ZEOOY beats the other by $48,848,133.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZEOOY + JNJ for your $10,000?

ZEOOY: 50%JNJ: 50%
100% JNJ50/50100% ZEOOY
Portfolio after 10yr
$31.52M
Annual income
$28,738,885.44/yr
Blended yield
91.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ZEOOY
No analyst data
Altman Z
3.0
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZEOOY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZEOOYJNJ
Forward yield1.99%2.13%
Annual dividend / share$0.19$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$63.02M$30.3K
Annual income after 10y$57,473,081.47$4,689.40
Total dividends collected$62.57M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ZEOOY vs JNJ ($10,000, DRIP)

YearZEOOY PortfolioZEOOY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,098$398.36$10,592$272.30+$506.00ZEOOY
2$12,702$826.37$11,289$357.73+$1.4KZEOOY
3$15,358$1,767.76$12,123$472.89+$3.2KZEOOY
4$20,429$3,995.38$13,141$629.86+$7.3KZEOOY
5$31,792$9,933.49$14,408$846.81+$17.4KZEOOY
6$62,913$28,895.24$16,021$1,151.60+$46.9KZEOOY
7$174,195$106,878.39$18,122$1,588.22+$156.1KZEOOY
8$739,524$553,135.30$20,930$2,228.20+$718.6KZEOOY
9$5,180,571$4,389,279.37$24,792$3,191.91+$5.16MZEOOY
10$63,016,292$57,473,081.47$30,274$4,689.40+$62.99MZEOOY

ZEOOY vs JNJ: Complete Analysis 2026

ZEOOYStock

Zeon Corporation engages in the elastomers, specialty materials, and other businesses. The company offers synthetic rubbers, such as general-purpose rubbers for use in automobile tire applications; and various specialty rubbers, including NBR and hydrogenated NBR. It also provides synthetic latex comprising styrene-butadiene copolymer latex, polybutadiene, acrylonitrile butadiene copolymer latex, acrylate latex, and soap-free latex for use in processed paper, fiber treatment agents, adhesives, paints, and rubber gloves; and materials for adhesive tapes and hot melt adhesives, binder for traffic paints, and concrete admixtures. In addition, the company offers specialty chemicals, such as synthetic aroma chemicals for flavors and fragrances; cyclopentene, cyclopentanone, and other derivatives for chemical synthesis; intermediates for pharmaceuticals and agrochemicals; and solvents and cleaning agents. Further, it provides electronic materials, rechargeable battery materials, and toners for the production of semiconductors, etching gas, and materials used in rechargeable battery production; and specialty plastics that include cyclo olefin polymers and fine processed products with cyclo olefin polymer for use in optical lenses, medical devices, and various general-purpose engineering plastics. Additionally, the company develops, manufactures, and sells cardiovascular and gastrointestinal medical equipment, as well as nutritional products; and licenses butadiene recovery and butene purification process technologies in approximately 23 countries worldwide. It also offers PENTAM, a resource- and energy-saving molded product. The company was founded in 1950 and is headquartered in Tokyo, Japan.

Full ZEOOY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ZEOOY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZEOOY vs SCHDZEOOY vs JEPIZEOOY vs OZEOOY vs KOZEOOY vs MAINZEOOY vs ABBVZEOOY vs MRKZEOOY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.